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ABSTRACT
Introduction Rheumatoid arthritis (RA) involves changes 
to foot structure and function, and there is an association 
between RA and foot pain. This pain affects those patient’s 
physical activity and experience of daily living. While there 
is clinical evidence for the value of foot orthoses (FO) on 
foot pain, there is a wide range of FO available and there 
is little evidence on the relative benefits of one orthoses 
type over another, especially in terms of their impact on 
physical activity and associated well- being. The aim of 
this study is to compare physical activity, general and foot 
health and foot health experiences in people with RA when 
wearing three different types of FO.
Methods and analysis A randomised controlled trial 
with three arms will compare the effects of (1) custom 
FO made using a direct adaptation technique, (2) custom 
FO made through a digital design and production process 
and (3) prefabricated orthoses. The primary outcome is 
physical activity measured using a GENEActiv bracelet. 
Secondary outcomes will be pain, function and disability 
and associated foot and general health evaluated using 
existing questionnaires. Semistructured interviews will 
identify patients’ experiences of the orthoses and living 
with RA.
Ethics and dissemination The study has been approved 
by the Portal de Ética de la Investigación Biomédica de 
Andalucía ethical committee (SPAR-001). The results will 
be disseminated regardless of the magnitude or direction 
of effect.
Trial registration number NCT03170947; Pre-results.
INTRODUCTION
The prevalence of foot involvement and foot 
pain in rheumatoid Arthritis (RA) is well 
documented, with an estimated 80%–90% of 
patients suffering foot pain in their lives.1 2 
The pain is due to structural and functional 
alterations associated with inflammation3 and 
impacts on physical activity of patients with 
RA.4 5 For example, Lee et al found that 42% 
of 176 patients with foot pain associated with 
RA failed to register any moderate/vigorous 
physical activity during a week- long evalua-
tion.6 Foot pain is strongly associated with a 
lack of physical activity.7 Furthermore, there 
is good evidence that foot pain reduces a 
person’s functional capacity and their quality 
of life8 9 and qualitative studies concluded 
that there is a negative impact on emotions 
and social activities.10 11
Foot orthoses (FO) are used to reduce foot 
pain and preserve joint mobility and position, 
and through this their aim is to keep patients 
physically active.12 It follows that the benefits 
of physical activity may be more accessible to 
patients using FO. A recent systematic review 
summarised the comparative effectiveness of 
the wide range of FOs suitable for patients 
with RA,13 although differences in their 
effects were non- significant or data incon-
clusive. In addition, studies that assess foot 
biomechanics or foot conditions (eg, reduc-
tion of forefoot plantar pressure or pain) do 
not include any measure of physical activity 
and patients wider experience of living with 
RA.14
This trial was designed in response to gaps 
in the current evidence base concerning FOs 
effects and the expectation that patient phys-
ical activity and experience of living with RA 
is affected by FO use. Furthermore, there is 
a long- standing debate on the relative merits 
of different types of FO and this trial is a 
response to this debate.15 We hypothesised 
that patients with RA and custom FO made 
Strengths and limitations of this study
 ► It is the first study that measures the effect of foot 
orthoses (FO) and the physical activity in patients 
with rheumatoid arthritis (RA).
 ► The combination of qualitative and quantitative data 
improves the overall knowledge of FO in patients 
with RA.
 ► The use of FO will be monitored by phone, but we 
cannot be sure that they use them everyday.
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either by direct adaptation technique or through a digital 
design and production process, will improve their activity 
level in comparison with patients with RA and prefab-
ricated orthoses. Our null hypothesis is that we will not 
find any significant difference between results from each 
custom orthoses and prefabricated orthoses, related to 
improve their physical activity increasing the period time 
when the patient is standing or walking. The aim of this 
study is to compare physical activity, general and foot 
health, and foot health experiences in people with RA 
when wearing three different types of FO.
METHODS AND ANALYSIS
Study design and setting
The design is a randomised clinical trial with the parallel 
group, three- arm trial with 1:1:1 allocation ratio. A mix of 
quantitative and qualitative measures will be adopted to 
address the objectives.
Patients will be recruited from the Hospital Virgen de 
las Nieves, Granada (Spain) from December 2019 and 
randomised to one of the three groups, each receiving 
a different type of foot orthosis(online supplementary 
file 2). Randomisation will be achieved using software 
to generate the allocation sequence (Gerard E. Dallal. 
Randomization. com 2008. http://www. randomization. 
com) and allocation concealed in envelopes. An indepen-
dent member of staff of Virgen de las Nieves hospital will 
perform the randomisation and allocation to groups.
Eligibility criteria
Patients aged 18 or over and satisfying 2010 RA classifi-
cation criteria (approved by the American College of 
Rheumatology and the European League Against Rheu-
matism)16 will be enrolled after giving informed written 
consent. Participants will be eligible if they have a history 
of bilateral subtalar and/or ankle and/or talonavicular 
pain, scoring at least 3.5 on a pain Visual Analogue Scale 
(VAS).17
Participants will be excluded if they present with 
concomitant musculoskeletal disease (eg, fibromyalgia), 
central or peripheral nervous system disease (eg, polio-
myelitis) or endocrine disorders (eg, diabetes) and insen-
sitivity to 10 g monofilaments applied to the medial and 
lateral plantar surfaces of the forefoot, and the plantar 
aspect of the great toe. Patients with a history of ortho-
paedic foot surgery, foot trauma in the last 6 months, 
those currently using FO or reliant on walking aids will 
be excluded.
Patients will be asked about the medication they use to 
monitor confounding variables during the period when 
using the FO.
Interventions
The systematic review by Healy et al concluded there is 
no gold- standard type of foot orthosis for people with 
RA.18 The three different types of FO chosen for this trial 
reflect a range of orthoses used in practice.19 They are 
all made from materials and shapes that are intended 
to reduce forefoot pressure, support foot structures and 
thereafter benefit the wearer in terms of reduced foot 
pain and associated disability. The primary differences 
between groups 1 and 2, and group 3, is the customis-
ation of the FO to individual foot shape and orthoses 
materials. The primary difference between groups 1 and 
2 is the method by which the FO are designed and manu-
factured, and the materials used for the orthoses. There 
are also differences between the groups in the cost of the 
orthoses. Participants will use the orthoses for 12 months 
and must wear the orthoses for 70% of the time they are 
wearing shoes to remain in the trial. Use of the orthoses 
will be determinate through the phone calls every month, 
understanding that one of the limits of this study could 
be that patients may not always provide a reliable answer.
Group 1
Custom orthoses will be made using a direct adaptation 
technique that involves a polyester resin and a combina-
tion of 1.2 mm Podiaflex for the rear and midfoot, and 
0.8 mm Podiaflex for the forefoot. There will also be a top 
layer of ethylene- vinyl acetate (EVA) (30 ShoreA) of 1.5 
mm and polyurethane (22 ShoreA) over the entire foot.
The shape of the orthosis is determined by heat 
moulding the resin to 90°C with a vacuum machine that 
combines heat and vacuum and placing the material 
against the foot (which is protected with a sock) under 
vacuum process. While the resin cools it takes the shape 
of the foot, while the heel is held a position described as 
subtalar joint neutral and the metatarsal heads pushed 
upwards to dorsiflex the ankle to a position of resis-
tance.20 21
Group 2
Custom- made orthoses will be made using a digital process 
and from 2 mm polypropylene with an EVA (30 ShoreA) 
of 1.5 mm and polyurethane (22 ShoreA) top layer.
The FO shape is determined by a three- dimensional 
(3D) scan (shape scan 100/IBV) of the feet, taken in a 
standing position. The FO shape is determined by a 3D 
scan (shape scan 100/IBV) of the feet, taken in a standing 
position. Each orthosis will be independently designed 
for left and right foot.22
Group 3
Prefabricated orthoses will the OPCT- OC Comfort 
Standard (Podiatech, https:// podiatech. es/). These 
full- length orthoses are available in increments of two 
European Union sizes and made from a base later of 5 
mm EVA under the heel and arches, and 2.5 mm and 4 
mm layers of EVA under the heel/arch and forefoot areas 
respectively. A top layer consists of EVA (30 ShoreA) of 
1.5 mm and polyurethane (22 ShoreA). (figure 1)
The orthoses will not be modified through the process 
due to the nature of the study, as it is an assessment of 1 
year and the FO will not change its structure or function 
much.
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If there were any discomfort during the delivery of the 
orthoses, the technician will make any necessary modifi-
cations, such as reduce the material under the arch.
Primary outcomes measures
The primary outcome measure is physical activity which 
will be measured using the actigraphy GENEActiv 
bracelet from Activinsights ( info@ geneactiv. co. uk). This 
combines a validated accelerometery technology with 
data on wear time, activity intensity and/or body position 
such as sitting or walking.23
Participants will wear the bracelet for a 7- day period 
on four different occasions: 1 week before orthoses first 
use, 6th week of orthoses use, and after 6 and 12 months 
of orthoses use. Adherence with accelerometer use will 
be tested through the accelerometer itself, which indi-
cates the period when the participants are not wearing it. 
Accelerometer will be deactivated when the patient stops 
wearing it.
Secondary outcomes measures
Secondary outcomes will be measures of pain, function 
and disability, and associated foot and general health. 
These will be captured using the following tools:
 ► VAS to measure pain, with extremes labelled as ‘no 
pain’ and ‘worst imaginable pain’.24
 ► Foot and Ankle Ability Measure (FAAM). This is a ques-
tionnaire to measure changes in participant function 
and disability. It is designed to measure the effect of 
pathology and any associated deterioration of physical 
function. It has 29 items, with items 1–21 relating to 
‘activities of daily life’ and 22–29 to ‘Sports’ subscales. 
Each question is scored 0–4, where 0 is ‘unable to do’ 
and 4 is able to achieve ‘without difficulty’.25
 ► Foot- Health Status Questionnaire (FHSQ). This is 
a questionnaire which contains 13 items covering 
foot pain, foot function, footwear and general foot 
health.26
The VAS will be completed before orthoses uses, after 
the first week of orthoses use and 6 and 12 months of 
orthoses use. The FAAM and FHSQ will be completed 
before orthoses uses and 6 and 12 months after orthoses 
use commences (online supplementary appendix 1).
Also, participants characteristics will be recorded.
Qualitative outcomes
To explore participant expectations and experiences of 
the orthoses use while having RA, qualitative data will be 
collected using unstructured interviews prior to, and after 
6 and 12 months of orthoses use. The initial interview 
topic list is:
 ► Tell me about your feet.
 ► Tell me about your physical activity.
 ► How much do your foot problems affect your activity?
 ► How much do your foot problems affecting your 
activity levels?
 ► Have your feet and any problems affected your quality 
of life?
 ► How important are your foot problems to you?
 ► How do you feel about wearing orthotic insoles?
 ► Do the orthotic insoles affect or impact your activity 
life?
Blinding and monitoring
Participants will be blind as to which group they are allo-
cated to and will not see the other two orthoses designs.
Questionnaire data will be collected prior to the partic-
ipant meeting clinician at each measurement point. Clin-
ical appointments after first orthoses use will be at 6 and 
12 months. All data will be entered into a database by a 
researcher independent of the clinician meeting partici-
pants, the process of making the orthoses and fitting the 
orthoses, and the researcher will be blinded to group allo-
cation because the researcher will not have access to the 
treatment selection.
Due to the aesthetics of the three orthoses, the clini-
cian cannot be blinded to group allocation, and the clini-
cian will not take part in the data collection because the 
design, manufacturing, administration and modification 
of the orthoses are going to be done by three indepen-
dent people. For the direct technique, a technician will 
undertake all design/manufacturing steps. For the digi-
tally designed/manufactured orthoses, a technician will 
undertake all the necessary steps. One investigator will 
telephone participants once every 2 weeks to maintain 
contact, support good compliance and record use of 
orthoses. Adverse events will be recorded as part of moni-
toring and appropriate safety measures. Statistical anal-
ysis will be performed by a statistician blinded to the study 
aims.
Figure 1 Group 1 (A) direct adaptation technique posterior 
view, group 1 (B) direct adaptation technique medial view, 
group 1 (C) direct adaptation technique anterior view. Group 
2 (A) CAD/CAM foot orthoses posterior view, group 2 (B) 
CAD/CAM medial view, group 2 (C) CAD/CAM anterior view. 
Group 3 (A) prefabricated orthoses posterior view, group 3 (B) 
prefabricated orthoses medial view, group 3 (C) prefabricated 
orthoses anterior view. CAD, Computer- Aided Design; CAM, 
Computer- Aided Manufacturing.
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Sample size
The sample size will be determinate by application of 
the EPIDAT (https://www. sergas. es/ Saude- publica/ 
EPIDAT? idioma= es) programme. Sample size calcula-
tions are based on an analysis of covariance adjusting for 
baseline of the outcome variable(GENEActiv bracelet), 
and assume a between- person SD of 10% of increase of 
walking in the main outcomes actigraphy GENEActiv 
bracelet.27 Following, the study will be designed to detect 
changes exceeding 0.8 (high effect size) with a type I 
error of 0.05 and a type II error of 0.2. This is based on 
prior recommendation of 15 participants per arm for 
pilot studies to estimate outcome variance and allows for 
a predicted attrition rate of 20% with a precision of ±5% 
with 95% confidence level.28 Due to this, we will recruit 15 
patients in each group.
Statistical analysis
Quantitative data will be assessed using SPSS (IBM SPSS 
Statistics: V.24, USA). Outcomes will be evaluated at 3, 6 
and 12 months of orthoses use. The primary time point 
will be the long- term follow- up 12 months. Quality of 
data will be assured by using range checks for data values. 
The database will be stored in a secure file that will be 
only accessed by encripted login. Moreover, exploratory 
analyses will be carried out to check the integrity of data, 
and the normality of distributions, by evaluating the asym-
metry and kurtosis, and the Kolmogorov- Smirnov test. 
Baseline data will be analysed to determine their distri-
bution and potential differences between groups. If so, 
baseline data will be used to adjust the final analysis by 
multivariable analyses. For continuous outcomes, analysis 
of variance test will be used in case of homoscedasticity (it 
will be checked by the Levene’s test). If homoscedasticity 
is not guaranteed, the Brown- Forsythe test will be used for 
hypothesis contrast. For qualitative outcomes, X2 test will 
be used. Finally, a multivariable analysis will be carried 
out by using a linear regression model, introducing those 
factors that showed a significant association in the bivar-
iant analysis, adjusted by baseline data.
The handle of missing data will be done across missing- 
data imputation process, to avoid pitfalls involved with 
listwise deletion. However, an analysis by intention to treat 
will be also performed, to compare the three analyses and 
to assess, in the absence of coincidence, the subgroups of 
patients who will not fulfil the study protocol, to identify 
possible causes of treatment dropout, before rejecting or 
accepting the null hypothesis
Interview analysis
The qualitative data derived through interviews will be 
assessed using thematical analysis and supported by NVivo 
(http://www. qsrinternational. com/ nvivo- spanish).
This protocol will have some limitations due the nature 
of the study. First, we cannot claim that all patients will be 
using their orthoses the whole period of our study. This 
is because the study will be undertaken in Spain, where 
there are very high temperatures in summer. This may 
make it difficult for the patients to wear close- toed shoes, 
thus limiting the orthoses use and interfering with the 
adherence to the treatment.
Second, according to the patients’ condition, they may 
suffer a flare- up during the study, which can alter their 
physical activity independently of the orthoses use.
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